The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.
September 27th 2024
Shyam A. Patel, MD, PhD, discusses findings from a meta-analysis of the effect of clonal hematopoiesis on outcomes for hematopoietic stem cell transplant.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Community Oncology Connections™: Selecting and Sequencing Therapy for Patients With DLBCL in an Era of Expanding Options
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma
September 8th 2022Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in this disease.
European Commission Grants Orphan Drug Designation to Nana-val for Peripheral T-cell Lymphoma
The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir for use as a potential therapeutic option in patients with peripheral T-cell lymphoma.
Emavusertib Is Active in Heavily Pretreated AML and High-Risk MDS With Targeted Mutations
September 7th 2022Emavusertib elicited antitumor activity when given as a monotherapy in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome that harbored a spliceosome or FLT3 mutation.
Real-World Data Highlight Efficacy of Ide-cel in Patients With Relapsed/Refractory Multiple Myeloma
September 6th 2022A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.
Fixed-Duration Glofitamab Elicits Early, Durable Complete Remissions in Relapsed/Refractory LBCL
Michael Dickinson, MBBS, expands on data from a phase 2 dose-expansion study of glofitamab in heavily pretreated, highly refractory large B-cell lymphoma, explains the effect bispecific antibodies could have on treatment, and highlights other research efforts surrounding glofitamab-based therapies.
SEL24/MEN1703 Demonstrates Early Efficacy, Tolerability in R/R AML With IDH1/2 Mutations
The first-in-class dual PIM/FLT3 kinase inhibitor, SEL24/MEN1703, showcased encouraging efficacy and a tolerable safety profile in patients with acute myeloid leukemia whose tumors harbor a IDH1/2 mutation.
Single-Agent Belantamab Mafodotin Elicits Activity in Heavily Pretreated Patients With R/R Myeloma
Belantamab mafodotin monotherapy demonstrated anticancer activity with a tolerable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.
Daratumumab-Containing Regimens Display PFS Benefit Across Myeloma Subgroups
September 1st 2022Daratumumab combinations elicited significant progression-free survival, overall survival, overall response rate, and minimal residual disease–negativity benefits vs control in pretreated patients with relapsed or refractory multiple myeloma across clinically relevant subgroups.
Approval Sought for Tafasitamab/Lenalidomide Combo in R/R DLBCL in Hong Kong
The Hong Kong Special Administrative Region’s Department of Health has accepted for review a biologics license application seeking the approval of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
FDA Allows Trial Enrollment to Resume for Single-Agent Emavusertib in AML/MDS
The FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Novel Combinations Could Spark Shift in Treatment Paradigm for Higher-Risk MDS
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Daiichi Sankyo Submits sNDA for Quizartinib in Newly Diagnosed FLT3-ITD+ AML in Japan
Daiichi Sankyo submitted a supplemental new drug application to Japan’s Ministry of Health, Labor, and Welfare for the use of quizartinib in patients with newly diagnosed, FLT3-ITD–positive acute myeloid leukemia.
EU Approves Asciminib for Ph+ CML in Chronic Phase After 2 or More TKIs
The European Commission has approved asciminib for the treatment of patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who received prior treatment with at least 2 TKIs
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.
Multiple Myeloma Armamentarium Is Set to Explode as Novel Agents Show Encouraging Early Data
Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.